Inhalation of fenoterol (Berotec) by asthmatic children: A clinical comparison with salbutamol, orciprenaline and isoprenaline.
Fenoterol (Berotec) has been administered by inhalation, via a Bennett nebulizer, to symptom-free asthmatic children aged 6 to 14 years. The effects of treatment on the results of respiratory function tests, pulse rate and blood pressure were followed. The effects of fenoterol have been compared with those of placebo, salbutamol, orciprenaline and isoprenaline. Inhalation of 1 mg of fenoterol produced effective bronchodilatation, which was more than a placebo effect and was comparable with the responses achieved with other known effective bronchodilators given by inhalation. It produced only a minor increase in heart rate at this dose level.
D000293:Adolescent; D000336:Aerosols; D000420:Albuterol / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use*; D008297:Male; D009921:Metaproterenol / Q000627:therapeutic use*; D010919:Placebos
D000336:Aerosols; D004983:Ethanolamines; D010919:Placebos; D005280:Fenoterol; D009921:Metaproterenol; D007545:Isoproterenol; D000420:Albuterol